Brief: Cambium Bio Says U.S. FDA Grants Fast Track Designation To Elate Ocular
09/12/2024 01:13
Dec 9 (Reuters) - Cambium Bio Ltd CMB.AX :
* FDA GRANTS FAST TRACK DESIGNATION
* US FDA GRANTS FAST TRACK DESIGNATION TO CAMBIUM BIO'S
ELATE
OCULAR
Further company coverage: CMB.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cambium Bio
See all newsAustralia's Cambium Bio hits near three-month high on share placement at premium
Brief: Cambium Bio Appoints Olga Smejkalova As Company Secretary
Australia's Cambium Bio gains after premium share placement
Brief: Cambium Bio Raises A$1 MLN At A$0.48 Per Share
Brief: Cambium Bio Receives A$2.4 Million Investment From Zheng Yang Biomedical Technology